荣昌生物:注射用泰它西普治疗干燥综合征上市申请获批

财中社
Jun 08

6月8日,荣昌生物(688331/09995)发布公告,公司收到国家药品监督管理局核准签发的药品注册证书,注射用泰它西普治疗干燥综合征(干燥病)的新适应症上市申请获批。  泰它西普是公司自主研发的全球首个BLyS/APRIL双靶点创新药,通过同时抑制BLyS和APRIL与B细胞表面受体结合,阻断B细胞异常分化和成熟,更好地控制疾病活动。  截至本公告披露日,泰它西普在中国已获得系统性红斑狼疮、...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10